aspirin has been researched along with adenosine 2',5'-diphosphate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dangelmaier, C; Daniel, JL; Jin, J; Kunapuli, SP; Smith, JB | 1 |
| Heptinstall, S; May, JA; Storey, RF | 1 |
2 other study(ies) available for aspirin and adenosine 2',5'-diphosphate
| Article | Year |
|---|---|
The P2Y1 receptor mediates ADP-induced p38 kinase-activating factor generation in human platelets.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Aspirin; Blood Platelets; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Platelet Activation; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2Y1; Signal Transduction; Thromboxane A2; Vasoconstrictor Agents | 2000 |
Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Degranulation; Dalteparin; Drug Synergism; Heparin; Hirudins; Humans; In Vitro Techniques; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12 | 2005 |